- anti-IL-25 monoclonal antibody candidate (LNR125.38) in development for treatment of CIP
- Unlike other CIP therapeutics, LNR125.38 significantly reduces tumor growth rather than promoting it
- Implications in all fibrotic and type 2 inflammatory conditions, with active R&D underway for pulmonary fibrosis, non-allergic asthma, atopic dermatitis, COPD, Ulcerative colitis, and others
- Licensing and partnership opportunities for additional indications
- Seasoned founding management has successfully launched multiple drugs
The Ideal Treatment for CIP
Protection from pulmonary fibrosis with tumor suppression
Executive Summary
![](https://lanierbio.com/wp-content/uploads/2023/06/IL-25-receptors-1-987x1024.jpg)
![](https://lanierbio.com/wp-content/uploads/2023/06/antibody.png)
LEAD INDICATION
Checkpoint Inhibitor Induced Pneumonitis and Interstitial Lung Disease
Up to 30% of cancer patients taking immune checkpoint inhibitors (ICls) will develop pneumonitis as a result of this therapy as more combinations and chronic administration becomes the norm.
Over 20% of those with checkpoint inhibitor pneumonitis (CIP) will die from respiratory failure – with an average 1 month progression free survival for severe CIP.
LEAD INDICATION
Checkpoint Inhibitor Induced Pneumonitis and Interstitial Lung Disease
Up to 30% of cancer patients taking immune checkpoint inhibitors (ICls) will develop pneumonitis as a result of this therapy as more combinations and chronic administration becomes the norm.
Over 20% of those with checkpoint inhibitor pneumonitis (CIP) will die from respiratory failure – with an average 1 month progression free survival for severe CIP.